NCCN Guidelines Updates: New Immunotherapy Strategies for …
For the use of immunotherapy in metastatic non–small cell lung cancer (NSCLC), the NCCN Guidelines for NSCLC reflect the importance of assessing levels of PD-L1 expression to determine the best use …
Immunotherapy Strategies in the Updated NCCN Guideline for NSCLC …
The updated National Comprehensive Cancer Network (NCCN) guideline for non–small-cell lung cancer (NSCLC; version 3.2019) is focused on improving patient outcomes with immunotherapy.
PD-L1 and TMB Testing of Patients… | College of American Pathologists
Apr 16, 2024 · The primary goal of this guideline was to develop evidence-based recommendations for the testing of immunotherapy biomarkers including program death ligand-1 (PD-L1) and tumor …
PD-L1 phenotype classification based on expression in tumor and …
Dec 5, 2025 · This study aimed to assess whether programmed cell death-ligand 1 (PD-L1) expression on tumor and immune cells (ICs) can guide first-line immunotherapy in advanced NSCLC.Methods …
NCCN 2025: Immune Checkpoint Inhibitors Expand ... - Pharmacy Times
Mar 29, 2025 · PD-L1 immune checkpoint inhibitors are now standard for early-stage non-metastatic non-small cell lung cancer (NSCLC), with neoadjuvant, adjuvant, and perioperative strategies …
Treatment Strategies for First-Line PD-L1-Unselected Advanced NSCLC…
Jul 30, 2025 · Stratified analyses clearly demonstrate that the magnitude of benefit in both OS and PFS is greatest in PD-L1 < 50% populations when chemotherapy is combined with PD-1/PD-L1 blockade, …
Immunotherapy Testing Recommendations Released
Apr 17, 2024 · In collaboration with several organizations, the College of American Pathologists (CAP) has released recommendations for testing of immunotherapy biomarkers, including PD-L1 and tumor …
Clinical Considerations for the Management of Advanced PD-L1 ≥50
Apr 11, 2025 · As a result, ≥50% PD-L1 TPS became an actionable biomarker in regulatory approvals and treatment guidelines, guiding immunotherapy decisions in advanced NSCLC.
High TMB in NSCLC and Increased Immune Infiltration and Improved ...
Jun 16, 2022 · Meaning These findings suggest that in NSCLC, a high number of nonsynonymous tumor mutations is associated with immune cell infiltration and inflammatory T-cell expression signatures, …
These findings support the potential utility of transcriptomics along with protein expression for assessing novel predictive biomarkers for IO. Furthermore, the distinct expression profiles of AICs identified in …